Full-mouth Periodontal Debridement and Metronidazole Gel in Patients With Chronic Periodontitis

NCT ID: NCT01938183

Last Updated: 2013-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis: metronidazole gel applied topically after periodontal debridement in smokers volunteers could improve clinical parameters when compared to metronidazole tablets + periodontal debridement. Method: 30 smokers with chronic periodontitis were randomly assigned into 3 groups: periodontal debridement combined with 3 g placebo gel; periodontal debridement combined with daily topical application of 3 g metronidazole benzoate gel (15%); and periodontal debridement combined with a daily single dose of 750 mg metronidazole. Clinical parameters evaluated were visible plaque, gingival bleeding, probing pocket depth and relative attachment level.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background. The benefit of adjunctive metronidazole on periodontal procedure in smokers with chronic periodontitis (CP) is uncertain. The authors compared the effect of metronidazole (Mtz) on full-mouth periodontal debridement (PD= 1 hour of ultrasonic calculus/plaque removal) in smokers with CP.

Methods. This pilot study involved 30 Individuals (having at least six teeth with a clinical attachment loss of ≥ 5 mm and probing pocket depth (PPD) of ≥5 mm) that were randomly assigned into three groups (n=10): 1) PD plus 3 g of placebo gel daily topical application 2) PD plus daily topical application of 3 g of 15% Mtz benzoate gel; and 3) PD plus a daily single dose of 750 mg Mtz (Flagyl®). Clinical parameters visible plaque index (VPI), gingival bleeding index (GBI), relative attachment level (RAL) and PPD; and the quantitative analysis (real-time PCR) of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia were assessed baseline, 1, 3 and 6 months after PD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Periodontitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

chronic periodontitis metronidazole

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Full-mouth PD+placebo gel

Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.

Group Type PLACEBO_COMPARATOR

Full-mouth periodontal debridement

Intervention Type PROCEDURE

full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour

placebo gel

Intervention Type DRUG

semi-solid suspension containing carbopol

Full-mouth PD+Metronidazole tablet

Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.

Group Type ACTIVE_COMPARATOR

Full-mouth periodontal debridement

Intervention Type PROCEDURE

full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour

Metronidazole tablet

Intervention Type DRUG

750 mg metronidazole tablets

Full-mouth PD+Metronidazole benzoate gel

Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.

Group Type ACTIVE_COMPARATOR

Full-mouth periodontal debridement

Intervention Type PROCEDURE

full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour

Metronidazole benzoate gel

Intervention Type DRUG

15% Mtz benzoate in semi-solid suspension containing carbopol (gel)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Full-mouth periodontal debridement

full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour

Intervention Type PROCEDURE

Metronidazole tablet

750 mg metronidazole tablets

Intervention Type DRUG

placebo gel

semi-solid suspension containing carbopol

Intervention Type DRUG

Metronidazole benzoate gel

15% Mtz benzoate in semi-solid suspension containing carbopol (gel)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PD MTZ tablet MTZ GEL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of chronic periodontitis
* presence of at least 6 periodontal pockets with a clinical attachment loss of ≥5 mm
* bleeding on probing (BOP)
* radiographic bone loss
* probing pocket depth higher or equal to 5 mm in at least six teeth
* at least 20 teeth in mouth (third molars excluded)
* an established smoking habit (at least 10 cigarettes per day for the past 4 years)

Exclusion Criteria

* periapical alterations in qualifying teeth
* medical disorders requiring prophylactic antibiotic therapy or interfering with the treatment
* periodontal treatment in the past 6 months
* use of drugs known to affect periodontal status (antibiotic, anti-inflammatory, anticonvulsant, immunosuppressant and calcium channel blocker) within the past 6 months
* orthodontic therapy
* pregnancy and lactation
* allergy to metronidazole
* any systemic diseases (e.g.: diabetes and immunological disorders)
Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Faculty Sao Leopoldo Mandic Campinas

OTHER

Sponsor Role collaborator

University of Campinas, Brazil

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Francisco Groppo

Full Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cristiane C Bergamaschi, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Campinas, Brazil

Francisco C Groppo, PhD

Role: STUDY_CHAIR

University of Campinas, Brazil

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Piracicaba Dental School

Piracicaba, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

References

Explore related publications, articles, or registry entries linked to this study.

Lorentz TC, Cota LO, Cortelli JR, Vargas AM, Costa FO. Prospective study of complier individuals under periodontal maintenance therapy: analysis of clinical periodontal parameters, risk predictors and the progression of periodontitis. J Clin Periodontol. 2009 Jan;36(1):58-67. doi: 10.1111/j.1600-051X.2008.01342.x. Epub 2008 Oct 30.

Reference Type BACKGROUND
PMID: 19017035 (View on PubMed)

Carvalho LH, D'Avila GB, Leao A, Goncalves C, Haffajee AD, Socransky SS, Feres M. Scaling and root planing, systemic metronidazole and professional plaque removal in the treatment of chronic periodontitis in a Brazilian population II--microbiological results. J Clin Periodontol. 2005 Apr;32(4):406-11. doi: 10.1111/j.1600-051X.2005.00720.x.

Reference Type BACKGROUND
PMID: 15811059 (View on PubMed)

Moeintaghavi A, Talebi-ardakani MR, Haerian-ardakani A, Zandi H, Taghipour S, Fallahzadeh H, Pakzad A, Fahami N. Adjunctive effects of systemic amoxicillin and metronidazole with scaling and root planing: a randomized, placebo controlled clinical trial. J Contemp Dent Pract. 2007 Jul 1;8(5):51-9.

Reference Type BACKGROUND
PMID: 17618330 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MTZ085-2006

Identifier Type: -

Identifier Source: org_study_id